Study of promotor -21 A/T polymorphism of catalase CAT (rs7943316) gene in patients with breast cancer

Abstract

Abstract Oxidative stress is implicated in many forms of cancer, and catalase is one of the most critical enzymes involved in the organic body's defensive mechanism against stress on antioxidation. Catalase shows a vital role in the body's primary defense versus oxidative stress. Several studies have indicated that CAT gene polymorphism plays an essential role in the pathogenesis of cancer. This study aimed to recognize the influence of the CAT (rs7943316) gene polymorphism on breast cancer progress in patients using a collection of blood samples from each subject. After the extraction of genomic DNA, the SNP rs7943316 analysis was performed using PCR, RFLP, and electrophoresis on agarose. finally visualized under UV light and analyzed with SPSS software (version 23). This study revealed that the higher genotype in the control subjects was AT genotype 19 (63.3%), followed by TT genotype 11 (36.7%), and AA genotype (0%). In the BC group, AT genotype was the higher 39 (55.7%), followed by TT genotype 24 (34.3%), and AA genotype 7 (10.0%). Individual carriers of the A/T and T/T type of genotype were less expected to develop BC [OR = 0.135, 95% CI = 0.0073-2.4882, P value = 0.178] and [OR = 0.1420, 95% CI = 0.0075-2.70, P value = 0.1943], respectively. In addition, there are no significant differences in frequencies of the T allele of the CAT gene (rs7943316) between breast cancer patients and control groups [OR = 0.67, 95% CI = 0.4002-1.4459, P value = 0.4039]. In brief, the current study’s results suggest no correlation between rs7943316 polymorphisms of CAT genes and the development of BC; the genotypes AA, AT, and TT have no potential risk for breast cancer in patient women.